Alzheimer's disease remains one of medicine's most stubborn challenges. Current drug options — particularly the amyloid-targeting antibody therapies — carry enormous price tags, serious side-effect risks including cerebral hemorrhage, and offer only modest benefit. A growing body of evidence, however, points toward metabolic and ketogenic interventions as a promising, lower-risk alternative, at least for a meaningful subset of patients. The key insight driving this approach: a hallmark of Alzheimer's is glucose hypometabolism — the brain's progressive inability to use its primary fuel — and ketones can step in where glucose fails.
Inflammation as the Upstream Driver
The prevailing amyloid hypothesis — that the buildup of amyloid plaques causes Alzheimer's — has accumulated significant baggage. There are people whose brains are dense with amyloid yet who remain cognitively sharp. A compelling alternative framing places systemic inflammation as the primary driver, with amyloid and tau accumulation as downstream consequences rather than root causes.
Animal studies support this view: injecting LPS (a potent inflammatory trigger) into mice rapidly accelerates amyloid progression. This matters because ketogenic diets and metabolic therapies don't merely shift energy metabolism — they are also among the most powerful dietary tools for reducing systemic inflammation. Inflammatory markers like high-sensitivity CRP drop substantially on these diets, sometimes to undetectable levels.
How Ketogenic Therapy May Help
The rationale for ketogenic intervention in Alzheimer's rests on three pillars working in concert:
- Suppressing neuroinflammation by reducing systemic inflammatory burden
- Improving glucose metabolism, partially restoring the brain's primary fuel pathway
- Elevating ketones as an alternative energy substrate, bypassing the glucose transport defect
Critically, the brain's ability to utilize ketones does not appear to decline with age the way glucose metabolism does. Dual PET scan research by Dr. Stephen Cunnane has demonstrated this directly: as we age, glucose uptake in the brain decreases, but ketone uptake remains preserved. This makes ketone-based therapy not just symptomatically useful but mechanistically well-grounded.
12:30
Dual glucose-ketone PET scan data showing age-related decline in brain glucose uptake but preserved ketone uptake
Watch at 12:30 →
What the Clinical Evidence Shows So Far
Rigorous, long-term randomized controlled trials are still ongoing, but acute studies are encouraging. Elevating ketone levels in patients with existing cognitive deficits reliably improves performance across a battery of cognitive assessments. The longer-term question — whether sustained ketone therapy slows or halts amyloid accumulation over years — is what current trials are designed to answer.
Early case evidence also offers a compelling signal. When AC-1202 (essentially caprylic triglyceride, a medium-chain triglyceride) was published by Sam Henderson in 2008, it improved Mini-Mental State Exam scores. Dr. Mary Newport, observing that research, gave her husband coconut oil and MCT oil; a subsequent case report documented years of stabilization. While anecdotal, the trajectory was striking enough to inform larger investigations.
Patient selection is likely to be decisive. Alzheimer's is a heterogeneous disease — some cases are primarily vascular, others involve excess glutamate toxicity, others are driven by pure energetic failure. The patients most likely to respond to ketogenic therapy are probably those who present with the most pronounced glucose hypometabolism on PET imaging. Including that as an enrollment criterion in future trials could dramatically sharpen the signal.
The Case for Comprehensive Metabolic Formulas
Rather than targeting a single pathway, the more promising direction may be a comprehensive metabolic formula combining agents that address Alzheimer's through complementary mechanisms. Candidate components already have individual supporting evidence:
- MCT oil / ketogenic agents — direct ketone precursors
- Creatine monohydrate — supports cellular energy buffering
- Alpha-ketoglutarate — mitochondrial support
- Alpha-GPC — cholinergic support, potentially most useful in the context of an existing cognitive deficit
- Lactate — an additional alternative brain fuel
The obstacle is largely structural: funding agencies are reluctant to finance multi-ingredient formula research because there is no clear patent or commercial pathway. Most academic funding flows toward single-molecule studies, leaving the combinatorial approach underfunded despite its theoretical advantages. Researchers like Dale Bredesen and Stephen Cunnane have been working toward more comprehensive approaches, but the field has yet to run a definitive trial on a full metabolic protocol.
Practical Considerations and Situational Use
For cognitive enhancement in otherwise healthy individuals, the evidence for components like alpha-GPC is thinner. It may work best in combination — alpha-GPC alongside MCT, caffeine, and L-theanine represents a well-reasoned nootropic stack, with the theanine moderating overstimulation and the MCT providing sustained ketone availability. However, alpha-GPC can be overstimulating for some people and may affect sleep quality, which argues for situational rather than daily use.
The same logic applies to fasting, which shares many of the metabolic effects of ketogenic diets. Using fasting strategically — during periods of high cognitive demand, during an inflammatory event, or when dealing with GI disturbance — may yield sharper benefits than treating it as a daily default. The underlying principle is consistent: metabolic interventions appear to confer their greatest benefit when there is a deficit or challenge to overcome, and for Alzheimer's patients facing a genuine brain energy crisis, that threshold is clearly met.
